NCT03878628View on ClinicalTrials.gov

Treatment With Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Aqueous Deficient Dry Eye Disease

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

February 20, 2023

Conditions
Dry EyeKerato Conjunctivitis SiccaAqueous Tear Deficiency
Interventions
DRUG

Adipose tissue-derived mesenchymal stem cells

CSCC\_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre

Trial Locations (1)

2200

Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT03878628 - Treatment With Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Aqueous Deficient Dry Eye Disease | Biotech Hunter | Biotech Hunter